Home/Filings/4/0000899243-21-004752
4//SEC Filing

Callori Fred 4

Accession 0000899243-21-004752

CIK 0001454789other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 6:45 PM ET

Size

10.7 KB

Accession

0000899243-21-004752

Insider Transaction Report

Form 4
Period: 2021-02-01
Callori Fred
Director
Transactions
  • Award

    Series X Convertible Preferred Stock

    2021-02-01$3009.53/sh+1,617$4,866,41030,920 total(indirect: By Perceptive Xontogeny Venture Fund, LP)
    Common Stock (1,617,000 underlying)
Footnotes (2)
  • [F1]Upon stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of common stock, each share of Series X Non-Voting Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.
  • [F2]On February 1, 2021, Issuer completed its private placement pursuant to that certain Stock Purchase Agreement dated January 27, 2021 (the "Private Placement"). In connection with the Private Placement, a limited partnership (the "Fund") in which the Reporting Person has an indirect pecuniary interest purchased shares of Series X Convertible Preferred Stock. The Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of his pecuniary interest therein.

Issuer

CATABASIS PHARMACEUTICALS INC

CIK 0001454789

Entity typeother

Related Parties

1
  • filerCIK 0001843393

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 6:45 PM ET
Size
10.7 KB